NewSquare Capital’s Lipocine LPCN Stock Holding History

NewSquare Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12	Closed	-$60	–	762
2023 Q2	$60	Hold	12	–	–	﹤0.01%	816
2023 Q1	$64	Hold	12	–	–	﹤0.01%	842
2022 Q4	$77	Buy	+12	New	+$87	﹤0.01%	777

Other funds holding LPCN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NewSquare Capital's LPCN Position: Q3 2023 in Review

NewSquare Capital sold out of Lipocine (LPCN) in Q3 2023, closing a stake of 12 shares — an estimated $60 sold.

NewSquare Capital first reported a position in LPCN in Q4 2022 and held it in 3 quarters. The position peaked at $77 in Q4 2022. 21 funds tracked by Wall St. Rank hold LPCN as of Q3 2023.

NewSquare Capital reported no remaining Lipocine position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 12 Lipocine shares in Q3 2023, an estimated $60.
NewSquare Capital first reported a position in Lipocine in Q4 2022 and held it in 3 quarters.
NewSquare Capital's Lipocine position peaked at $77 in Q4 2022.
21 funds tracked by Wall St. Rank held Lipocine as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.